# N4 Pharma make significant strides with optimisation work

- Link: https://www.directorstalkinterviews.com/n4-pharma-make-significant-strides-with-optimisation-work/412935686
- Published: 2020-11-05T07:06:00+00:00
- Author: Giles

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided the 
following update on its ongoing work programmes.

**Optimisation**

The optimisation programme is investigating different formulations of Nuvec® including
the type of Polyethylenimine (“PEI”), the requirement for phosphonation and the 
ratio of DNA/Nuvec® amongst other things. This work is progressing well and the 
Company is pleased to update that it has successfully developed different options
to make a fully monodispersed formulation of Nuvec® loaded with plasmid DNA. Initial
studies have also demonstrated that Nuvec® loaded with a plasmid DNA can be dried,
stored at room temperature and reconstituted without any degradation of DNA. This
formulation is now being stored over different periods after which it will be reconstituted
and tested _in vitro_ to demonstrate transfection has been maintained. Demonstrating
formulation stability would be an important milestone given that stable, easy to
store and easy to use vaccines are a major challenge for developers.

The Directors believe that demonstrating Nuvec® can be consistently formulated with
DNA or mRNA and dry stored for later use would give Nuvec® a considerable commercial
advantage as a delivery technology compared to lipid based mRNA systems that require
substantial freezing or electroporation based DNA systems which are expensive and
difficult to use. As this work concludes the Company will look to incorporate the
key findings into the planned optimised _in vivo_ study.

**Covid-19 Proof of Concept Programme and In Vivo study**

The plan for the unoptimised Nuvec® _in vivo_ study to compare the reactions of 
Nuvec® loaded with the Coronavirus plasmid and another generic plasmid in generating
relevant antibodies, has now been finalised and the study will commence shortly.

Plans for the optimised Nuvec® _in vivo_ study continue to evolve with the optimisation
programme introducing several variables (as detailed above) which the Company will
seek to compare and analyse as part of this study. As with the unoptimised study,
the Company will be comparing both the Coronavirus plasmid and other DNA plasmids
and it is expected that this work will commence in early 2021, subject to finalisation
with the Contract Research Organisation.

**Oral Application**

Feasibility work continues on Nuvec® as a solution to the challenges faced in the
delivery of vaccines orally. The Company expects to have some data following the
results of planned studies as to its viability towards the end of this year. Development
of an orally administered vaccine has significantly greater challenges than a subcutaneous
injection. One important aspect is that the DNA plasmid may be subject to damage
and breakdown by gastric acid and other digestive processes. However, the Company
has now demonstrated that Nuvec® protects plasmid DNA from both acid and nuclease
digestion. This result gives the Company confidence that further investigation of
this route of administration using Nuvec® is merited.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> “We are pleased to have made significant strides with our optimisation work and
> are currently analysing the findings. We are examining how these will feed into
> the optimised strand of the pending _in vivo_ study. The unoptimised side of this,
> which involves our first full _in vivo_ study utilising the Coronavirus DNA plasmid,
> is due to commence imminently.
> “Taken together with the work into oral applications and the ongoing technology
> transfer for the manufacture of Nuvec®, we are entering a pivotal time for the
> Company over the next six months and I look forward to providing further updates
> as each work stream progresses.”

You may also enjoy listening to our [interview with N4 Pharma](https://www.directorstalkinterviews.com/n4-pharma-optimisation-work-shows-the-versatility-of-nuvec-interview/412935680)
CEO Nigel Theobald on todays news.

Share on:
